Laurel M. Adams

2.0k total citations
47 papers, 1.2k citations indexed

About

Laurel M. Adams is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, Laurel M. Adams has authored 47 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 15 papers in Molecular Biology and 9 papers in Surgery. Recurrent topics in Laurel M. Adams's work include Nausea and vomiting management (8 papers), Cancer Treatment and Pharmacology (7 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). Laurel M. Adams is often cited by papers focused on Nausea and vomiting management (8 papers), Cancer Treatment and Pharmacology (7 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). Laurel M. Adams collaborates with scholars based in United States, United Kingdom and Netherlands. Laurel M. Adams's co-authors include Susan M. Fischer, Suren N. Sehgal, Robert L. Ullrich, M. C. Jernigan, Lisa Smurr Walters, Matthew Borgia, Linda Resnik, Jennifer Y. Chang, Janet Sredy and Daniel R. Budman and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Laurel M. Adams

47 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Laurel M. Adams United States	19	525	269	162	137	133	47	1.2k
Louisa Balázs United States	20	1.1k 2.1×	248 0.9×	103 0.6×	131 1.0×	94 0.7×	39	1.7k
Steven J. Miller United States	23	544 1.0×	158 0.6×	151 0.9×	122 0.9×	308 2.3×	48	1.3k
Yu-Chuen Huang Taiwan	20	529 1.0×	113 0.4×	88 0.5×	131 1.0×	106 0.8×	59	1.2k
Ke Ma China	22	623 1.2×	442 1.6×	232 1.4×	175 1.3×	144 1.1×	66	1.4k
M. Furuya Japan	17	544 1.0×	199 0.7×	235 1.5×	97 0.7×	130 1.0×	32	1.4k
Yujun Xu China	22	445 0.8×	214 0.8×	114 0.7×	165 1.2×	175 1.3×	64	1.3k
Lin Qi China	17	403 0.8×	126 0.5×	129 0.8×	126 0.9×	68 0.5×	47	1.3k
Sarah Tonack Germany	20	540 1.0×	140 0.5×	116 0.7×	126 0.9×	130 1.0×	28	1.1k
Kathrin Weyer Denmark	21	520 1.0×	107 0.4×	97 0.6×	121 0.9×	221 1.7×	47	1.5k
Dominick G. A. Burton United Kingdom	17	736 1.4×	179 0.7×	139 0.9×	201 1.5×	89 0.7×	21	1.7k

Countries citing papers authored by Laurel M. Adams

Since Specialization

Citations

This map shows the geographic impact of Laurel M. Adams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurel M. Adams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurel M. Adams more than expected).

Fields of papers citing papers by Laurel M. Adams

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurel M. Adams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurel M. Adams. The network helps show where Laurel M. Adams may publish in the future.

Co-authorship network of co-authors of Laurel M. Adams

This figure shows the co-authorship network connecting the top 25 collaborators of Laurel M. Adams. A scholar is included among the top collaborators of Laurel M. Adams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laurel M. Adams. Laurel M. Adams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Münster, Pamela N., Rahul Aggarwal, David S. Hong, et al.. (2015). First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clinical Cancer Research. 22(8). 1932–1939. 83 indexed citations

Brady, Joanne E., Pippa Corrie, Ian Chau, et al.. (2013). An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer. Investigational New Drugs. 31(5). 1228–1235. 9 indexed citations

Srinivasan, Ramaprasad, Donald P. Bottaro, Toni K. Choueiri, et al.. (2012). Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644).. Journal of Clinical Oncology. 30(5_suppl). 372–372. 6 indexed citations

Shapiro, Geoffrey I., Stewart W. McCallum, Laurel M. Adams, et al.. (2012). A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors. Investigational New Drugs. 31(3). 742–750. 38 indexed citations

Münster, Pamela N., Ruud van der Noll, Jennifer M. Specht, et al.. (2012). PI3K Kinase Inhibitor GSK2126458 (GSK458): Clinical Activity in Select Patient (PT) Populations Defined by Predictive Markers (STUDY P3K112826). Annals of Oncology. 23. ix153–ix154. 11 indexed citations

Resnik, Linda, et al.. (2012). Development and Evaluation of the Activities Measure for Upper Limb Amputees. Archives of Physical Medicine and Rehabilitation. 94(3). 488–494.e4. 99 indexed citations

Heath, Elisabeth I., Lisa Malburg, Shelby D. Gainer, et al.. (2011). A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors. Investigational New Drugs. 30(4). 1566–1574. 33 indexed citations

Adams, Laurel M., Brendan M. Johnson, John W. Bauman, et al.. (2010). Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer. Cancer Chemotherapy and Pharmacology. 67(4). 783–790. 5 indexed citations

Zamuner, Stefano, et al.. (2010). Effect of single and repeat doses of casopitant on the pharmacokinetics of CYP450 3A4 substrates midazolam and nifedipine. British Journal of Clinical Pharmacology. 70(4). 537–546. 11 indexed citations

10.

Johnson, Brendan M., Laurel M. Adams, Ke Zhang, et al.. (2010). Ketoconazole and Rifampin Significantly Affect the Pharmacokinetics, But Not the Safety or QTc Interval, of Casopitant, a Neurokinin‐1 Receptor Antagonist. The Journal of Clinical Pharmacology. 50(8). 951–959. 13 indexed citations

11.

Johnson, Brendan M., et al.. (2009). Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone. Supportive Care in Cancer. 17(9). 1177–1185. 14 indexed citations

12.

Adams, Laurel M., Brendan M. Johnson, Ke Zhang, et al.. (2009). Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron. Supportive Care in Cancer. 17(9). 1187–1193. 7 indexed citations

13.

Jonge, Maja J.A. de, Anne E. O’Donnell, Rik A. Brooimans, et al.. (2006). A Phase I Study of a New Nucleoside Analogue, OSI-7836, Using Two Administration Schedules in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 12(9). 2841–2848. 6 indexed citations

14.

Kreis, Willi, et al.. (2001). Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells. British Journal of Cancer. 85(9). 1403–1411. 25 indexed citations

15.

Budman, Daniel R., et al.. (2000). Synergism of Cytotoxic Effects of Vinorelbine and Paclitaxel in Vitro. Cancer Investigation. 18(8). 695–701. 35 indexed citations

16.

Robinson, Simon P., et al.. (1997). Inhibition of Leukotriene B4 (LTB4) in Human Neutrophils by L-Threo-Dihydrosphingosine. Advances in experimental medicine and biology. 400A. 387–392. 4 indexed citations

17.

Sredy, Janet, et al.. (1992). Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice. Clinical & Experimental Immunology. 89(2). 174–178. 65 indexed citations

18.

Caccese, Robert, et al.. (1991). Inhibition of interleukin-1 (IL-1) induced neutral proteases from rabbit articular chondrocytes by WY-46,135 and WY-48,989. Inflammation Research. 34(1-2). 223–225. 14 indexed citations

19.

Ullrich, Robert L., M. C. Jernigan, & Laurel M. Adams. (1979). Induction of Lung Tumors in RFM Mice after Localized Exposures to X Rays or Neutrons. Radiation Research. 80(3). 464–464. 47 indexed citations

20.

Ullrich, Robert L., Laurel M. Adams, & J. B. Storer. (1977). The effects of combined radiation therapy and immunotherapy with Corynebacterium parvum on the growth and metastases of the line 1 lung carcinoma. Proceedings of the American Association for Cancer Research. 18. 15. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact